Pr KURTZ Jean-Emmanuel

Characteristics and outcome of intra-abdominal desmoid-type fibromatosis.

Penel N, Toulmonde M, Wallet J, LE Cesne A, Bonvalot S, Corradini N, Valentin T, Chaigneau L, Bertucci F, Guillemet C, Bay JO, Dubray-Longeras P, Kurtz JE, Salas S, Bozec L, Thery J, Le Deley MC, Blay JY

Eur J Surg Oncol. 2026 05 19;52(7):111903

Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25).

Joly F, Anota A, Chabaud S, Cropet C, Priou F, Harter P, Pignata S, Palacio I, Petru E, Kobayashi H, Vergote I, Parma G, Mäenpää J, Raymond E, Ataseven B, Pisano C, Lainez N, Tsibulak I, Yonemori K, Vuylsteke P, Lapresa MT, Mirza MR, Bouchaert P, Buderath P, Lorusso D, Herrero A, Eberst L, Burges A, Scambia G, Ortega E, Guillemet C, Pujade-Lauraine E, Kurtz JE, Ray-Coquard I

J Natl Cancer Inst. 2026 04 24;:

Molecular taxonomy of pancreatic neuroendocrine tumors reveals BEND2-fusions-driven transcriptional plasticity and therapeutic vulnerabilities.

Lu X, Baltzinger P, Xu L, Fattori A, Bazai SK, Alhourani F, Chenard MP, Bachellier P, Addeo P, Debien V, Vacheret C, Imperiale A, Pessaux P, Cheng W, Balzinger M, Kurtz JE, Davidson I, Su X, Goichot B, Malouf GG

Cell Rep Med. 2026 03 6;:102642

Impact of Social Media on Adolescents and Young Adults with Solid Tumors or Hematological Malignancies: A Multicenter Study.

Martin S, Gantzer J, Entz-Werle N, Paillard C, Bilger K, Fritsch A, Geoffrois L, Calcagno F, Gaulier CC, Noal S, Kurtz JE

J Adolesc Young Adult Oncol. 2026 02 27;:21565333261426289

Determinants of morbidity and local control after cryoablation of sporadic extra-abdominal desmoid tumors.

Blondé P, Cazzato RL, Gantzer J, Steffen D, De Marini P, Bonnard L, Orkut S, Kurtz JE, Gangi A

Eur J Surg Oncol. 2026 01 31;52(4):111456

[French recommendations for clinical practice, Nice-Saint-Paul-de-Vence 2024-2025: Management of localized cervical cancer].

Chargari C, Martinez A, Michels J, Lecuru F, Combe P, Kurtz JE, Bello-Roufai D, Prulhière K, Genestie C, Balleyguier C, Ducassou A, Demontoy S, Joly F, Frenel JS, Berton D, Rousset-Jablonski C, Ray-Coquard I

Bull Cancer. 2026 01 29;:

Long-term quality of life in non-epithelial ovarian cancer survivors: TMRG-GINECO-Vivrovaire rare tumors case-control study.

Dubot C, Ray-Coquard I, Lequesne J, Pautier P, Renaud T, Selle F, Berton-Rigaud D, Frank S, De La Motte Rouge T, Kalbacher E, Provansal M, Blonz C, Orfeuvre H, Alexandre J, Augereau P, Nadeau C, Kurtz JE, Hanvic B, Fresneau B, Ahmed-Lecheheb D, Christy F, Grellard JM, Clarisse B, Gernier F, Joly F

BMC Med. 2025 12 12;:

Outcome of Metastatic Biliary Tract Cancer Harbouring or Alterations: A Retrospective Observational Real-World Study from a French Cohort.

Barbe-Richaud JB, Moinard-Butot F, Cotton M, Bigot C, Rivière P, Belletier C, Pencreach E, Karouby D, Chiappa P, Eberst L, Kurtz JE, Ben Abdelghani M

J Clin Med. 2025 09 24;14(19):

Outcome of 1773 superficial non-dermatofibrosarcoma sarcomas A French Sarcoma Group study (FSG) from the NETSARC database.

Bompas E, Campion L, Toulmonde M, Le Cesne A, Saint-Jean M, Lebbe C, Valentin T, Rios M, Duffaud F, Firmin N, Carrère S, Piperno-Neumann S, Perrin C, Ropars M, Bonvalot S, Watson S, Tzanis D, Boudou-Roquette P, Tlemsani C, de Percin S, Desmoulin I, Causeret S, Ducoulombier A, Saada-Bouzid E, Bertucci F, Kurtz JE, Gantzer J, Brahmi M, Dufresne A, Gouin F, Meeus P, Italiano A, Michot A, Spatalo-Ceruso M, Verret B, Honoré C, Ryckewaert T, Decanter G, Mattei JC, Gangloff D, Salas S, Narciso B, Moreau-Bachelard C, Le Nail LR, Dubray-Longeras P, Fiorenza F, Chagneau L, Guillemet C, Penel N, Blay JY

Eur J Cancer. 2025 09 12;229:115788

Relative Dose Intensity of Trabectedin and Outcome of Advanced L-Sarcomas.

Poitureau S, Le Deley MC, Brahmi M, Bompas E, Kurtz JE, Nannini S, Perrin C, Lebellec L, Ryckewaert T, Ould-Ammar R, Leguillette C, Blay JY, Penel N

Cancer Med. 2025 08;14(16):e71131

'Knowing and Treating Kosaki/Penttinen syndrome' international collaborative consortium: recommendations for follow-up, natural history and a real-life observational study about safety and efficacy profile of tyrosine kinase inhibitors.

Bouhatous YM, Bredrup C, Maurer A, Mirakovska L, Foster A, Kosaki K, Jost C, Demoulin JB, Luu M, Vabres P, Kurtz JE, Schaefer E, Guimier A, Cormier-Daire V, Lim D, Thompson S, Olson L, Kwon HR, Aguirre-Rodriguez C, Hernandez-Dorronsoro U, Martinez-Soroa I, Iznardo H, Mascaró JM, Baselga E, Kalantari S, Mussa A, Gazzin A, Carli D, Svinvik I, Mutlu-Albayrak H, Bluefeather S, Zarate Y, Takenouchi T, Naicker T, Chateau A, Gokhul A, Dube-Pule A, Haniffa M, Ong Peitee W, Nordgren A, Carpentier M, Binquet C, Briffaut AS, Bal L, Pond D, Rustad CF, Bardou M, Faivre L

J Med Genet. 2025 07 24;:

DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients.

Cherifi F, Ray-Coquard I, Rubio MJ, Paoletti X, Lorusso D, Choi CH, Hasegawa K, Tan DSP, Hudson E, Davis A, Tognon G, Lheureux S, Vardar Key MA, Kurtz JE, Alexandre J, Joly F

Future Oncol. 2025 05 5;:1-11

Clinical description and development of a prognostic score for neurofibromatosis type 1 (NF1)-associated GISTs: a retrospective study from the NETSARC.

Cuvelier C, Brahmi M, Sobhani I, Verret B, Grancher A, Penel N, Toulmonde M, Lahlou W, Dupuis H, Calavas L, Muller M, Watson S, Bruyat D, Poumeaud F, Chaigneau L, Manfredi S, Lecomte T, Bertucci F, Ghiringhelli F, Pracht M, Mourthadhoi F, Monceau-Baroux L, Helyon M, Kurtz JE, Roquin G, Regenet N, Vinches M, Tougeron D, Wolkenstein P, Blay JY, Bouche O, Hautefeuille V

ESMO Open. 2025 03 4;10(3):104477

Real-world outcomes of metastatic cancer patients hospitalized at initial diagnosis: ONIRIS, a national study.

Vercueil C, Varnier R, Seban R, Ciaptacz L, Pavillet J, Fraisse C, Darbas T, Abdallahoui S, Cox D, Martin S, Trensz P, Kurtz JE, Gantzer J, Amé S, Bouleuc C, Chvetzoff G, Eberst L

Support Care Cancer. 2025 02 3;33(2):145

Incorporating immune checkpoint inhibitors in epithelial ovarian cancer.

Bogani G, Moore KN, Ray-Coquard I, Lorusso D, Matulonis UA, Ledermann JA, González-Martín A, Kurtz JE, Pujade-Lauraine E, Scambia G, Caruso G, Raspagliesi F, Colombo N, Monk BJ

Gynecol Oncol. 2025 01 6;193:30-40

Improving real-world evaluation of patient- and physician-reported tolerability: niraparib for recurrent ovarian cancer (NiQoLe).

Joly F, Bazan F, Garbay Decoopman D, Ouldbey Y, Follana P, Champeaux-Orange É, Legouffe E, Brachet PE, Spaeth D, Combe P, Hardy-Bessard AC, Selle F, Grenier J, Lebreton C, Derbel O, Bonnet E, Fournel P, Fernandez Diez Y, Delecroix V, Emambux S, Alexandre J, Grellety T, Mille D, Orfeuvre H, Favier C, Le Roux D, Mouret-Reynier MA, Quesada S, Kurtz JE

JNCI Cancer Spectr. 2024 12 14;:

Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial.

Azaïs H, Brochard C, Taly V, Benoit L, Ferron G, Ray-Coquard I, You B, Abadie-Lacourtoisie S, Lebreton C, Venat L, Louvet C, Favier L, Blonz C, Dohollou N, Malaurie E, Dubot C, Kurtz JE, Pujade-Lauraine E, Rouleau E, Leary A, Bats AS, Blons H, Laurent-Puig P

Gynecol Oncol. 2024 12 12;192:145-154

Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial.

Mirza MR, Bjørge L, Marmé F, Christensen RD, Gil-Martin M, Auranen A, Ataseven B, Rubio MJ, Salutari V, Luczak AA, Runnebaum IB, Redondo A, Lindemann K, Trillsch F, Ginesta MPB, Roed H, Kurtz JE, Petersson KS, Nyvang GB, Sehouli J

Gynecol Oncol. 2024 12 9;192:128-136

Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp.

Rodrigues M, Ramtohul T, Rampanou A, Sandoval JL, Houy A, Servois V, Mailly-Giacchetti L, Pierron G, Vincent-Salomon A, Cassoux N, Mariani P, Dutriaux C, Pracht M, Ryckewaert T, Kurtz JE, Roman-Roman S, Piperno-Neumann S, Bidard FC, Stern MH, Renault S

Nat Commun. 2024 10 14;15(1):8851

The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research.

Moniot A, Schneider C, Chardin L, Yaniz-Galende E, Genestie C, Etiennot M, Henry A, Drelon C, Le Formal A, Langlois B, Venat L, Louvet C, Favier L, Lortholary A, Berton-Rigaud D, Dohollou N, Desauw C, Fabbro M, Malaurie E, Dubot C, Kurtz JE, Bonichon Lamichhane N, Pujade-Lauraine É, Jeanne A, Leary A, Dedieu S

Mol Cancer. 2024 08 14;23(1):166

Early palliative care and overall survival in patients with metastatic upper gastrointestinal cancers (EPIC): a multicentre, open-label, randomised controlled phase 3 trial.

Adenis A, Da Silva A, Ben Abdelghani M, Bourgeois V, Bogart E, Turpin A, Evin A, Proux A, Galais MP, Jaraudias C, Quintin J, Bouquet G, Samalin E, Bremaud N, Javed S, Henry A, Kurtz JE, Cornuault-Foubert D, Vandamme H, Lucchi E, Pannier D, Belletier C, Paul M, Touzet L, Penel N, Chvetzoff G, Le Deley MC

EClinicalMedicine. 2024 08;74:102470

Desmoid fibromatosis: IR (sometimes) to the rescue for an atypical disease.

Garnon J, Cazzato RL, Autrusseau PA, Koch G, Weiss J, Gantzer J, Kurtz JE, Gangi A

Br J Radiol. 2024 07 12;:

Current Management of Desmoid Tumors: A Review.

Kasper B, Baldini EH, Bonvalot S, Callegaro D, Cardona K, Colombo C, Corradini N, Crago AM, Dei Tos AP, Dileo P, Elnekave E, Erinjeri JP, Navid F, Farma JM, Ferrari A, Fiore M, Gladdy RA, Gounder M, Haas RL, Husson O, Kurtz JE, Lazar AJ, Orbach D, Penel N, Ratan R, Raut CP, Roland CL, Schut AW, Sparber-Sauer M, Strauss DC, Van der Graaf WTA, Vitellaro M, Weiss AR, Gronchi A,

JAMA Oncol. 2024 06 20;:

PEC-PRO: A new prognostic score from a series of 87 patients with localized perivascular epithelioid cell neoplasms (PEComas) treated with curative intent.

Gantzer J, Toulmonde M, Severac F, Chamseddine AN, Charon-Barra C, Vinson C, Hervieu A, Bourgmayer A, Bertucci F, Ryckewaert T, Valentin T, Firmin N, Chaigneau L, Bompas E, Follana P, Rioux-Leclercq N, Soibinet-Oudot P, Bozec L, Le Loarer F, Weingertner N, Chevreau C, Duffaud F, Blay JY, Kurtz JE, Schöffski P, Brahmi M, Malouf GG

Cancer. 2024 03 12;:

Improved nationwide survival of sarcoma patients with a network of reference centers.

Blay JY, Penel N, Valentin T, Anract P, Duffaud F, Dufresne A, Verret B, Cordoba A, Italiano A, Brahmi M, Henon C, Amouyel T, Ray-Coquard I, Ferron G, Boudou-Rouquette P, Tlemsani C, Salas S, Rochwerger R, Faron M, Bompas E, Ducassou A, Gangloff D, Gouin F, Firmin N, Piperno-Neumann S, Rios M, Ropars M, Kurtz JE, Le Nail LR, Bertucci F, Carrere S, Llacer C, Watson S, Bonvalot S, Leroux A, Perrin C, Gantzer J, Pracht M, Narciso B, Monneur A, Lebbe C, Hervieu A, Saada-Bouzid E, Dubray-Longeras P, Fiorenza F, Chaigneau L, Nevieres ZM, Soibinet P, Bouché O, Guillemet C, Spano JP, Ruzic JC, Isambert N, Vaz G, Meeus P, Karanian M, Ngo C, Coindre JM, De Pinieux G, Le Loarer F, Ducimetiere F, Chemin C, Morelle M, Toulmonde M, Le Cesne A

Ann Oncol. 2024 01 19;:

Management of a rare mandibular giant cell tumor of bone by neoadjuvant denosumab therapy and surgery: A 4-year follow-up case report.

Klienkoff P, Weingertner N, Geyer L, Gros CI, Kurtz JE, Bornert F

Int J Surg Case Rep. 2023 10 30;112:108980

Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial.

Kurtz JE, Pujade-Lauraine E, Oaknin A, Belin L, Leitner K, Cibula D, Denys H, Rosengarten O, Rodrigues M, de Gregorio N, Martinez García J, Petru E, Kocián R, Vergote I, Pautier P, Schmalfeldt B, Gaba L, Polterauer S, Mouret Reynier MA, Sehouli J, Churruca C, Selle F, Joly F, D'Hondt V, Bultot-Boissier É, Lebreton C, Lotz JP, Largillier R, Heudel PE, Heitz F,

J Clin Oncol. 2023 08 29;:JCO2300529

Characteristics, management and outcomes of active cancer patients with cardiogenic shock.

Merdji H, Gantzer J, Bonello L, Lamblin N, Roubille F, Levy B, Champion S, Lim P, Schneider F, Cariou A, Khachab H, Bourenne J, Seronde MF, Schurtz G, Harbaoui B, Vanzetto G, Quentin C, Curtiaud A, Kurtz JE, Combaret N, Marchandot B, Lattuca B, Biendel C, Leurent G, Bataille V, Gerbaud E, Puymirat E, Bonnefoy E, Aissaoui N, Delmas C

Eur Heart J Acute Cardiovasc Care. 2023 07 6;:

Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022–2023 : Prise en charge du cancer du col de l'utérus avancé

Pautier P, Genestie C, Gladieff L, Kurtz JE, Lortholary A, de La Motte Rouge T, Gaillard AL, Ducassou A, Dubot C, Rouleau E, Narducci F, Demontoy S, Hennequin C

Bull Cancer. 2023 06;110(6S):6S44-6S50

SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistance.

Vokshi BH, Davidson G, Tawanaie Pour Sedehi N, Helleux A, Rippinger M, Haller AR, Gantzer J, Thouvenin J, Baltzinger P, Bouarich R, Manriquez V, Zaidi S, Rao P, Msaouel P, Su X, Lang H, Tricard T, Lindner V, Surdez D, Kurtz JE, Bourdeaut F, Tannir NM, Davidson I, Malouf GG

Nat Commun. 2023 05 26;14(1):3034

Genomic profiling of a metastatic anaplastic melanocytic neuroectodermal tumor arising from a mature thymic teratoma as part of a mediastinal germ cell tumor.

Mayeur S, Lhermitte B, Gantzer J, Molitor A, Stemmelen T, Meyer S, Kolmer A, Kurtz JE, Bahram S, Carapito R

Cold Spring Harb Mol Case Stud. 2023 04;9(2):

Precision pain management in interventional radiology.

Bauones S, Cazzato RL, Dalili D, Koch G, Garnon J, Gantzer J, Kurtz JE, Gangi A

Clin Radiol. 2023 04;78(4):270-278

Pain in desmoid-type fibromatosis: prevalence, determinants, and prognosis value.

Penel N, Bonvalot S, Le Deley MC, Italiano A, Tlemsani C, Pannier D, Leguillette C, Kurtz JE, Toulmonde M, Thery J, Orbach D, Dubray-Longeras P, Verret B, Bertucci F, Guillemet C, Laroche L, Dufresne A, Blay JY, Le Cesne A

Int J Cancer. 2023 03 8;:

A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer.

Blanc-Durand F, Yaniz-Galende E, Llop-Guevara A, Genestie C, Serra V, Herencia-Ropero A, Klein C, Berton D, Lortholary A, Dohollou N, Desauw C, Fabbro M, Malaurie E, Bonichon-Lamaichhane N, Dubot C, Kurtz JE, de Rauglaudre G, Raban N, Chevalier-Place A, Ferron G, Kaminsky MC, Kramer C, Rouleau E, Leary A

Gynecol Oncol. 2023 03 1;171:106-113

Heritable defects in telomere and mitotic function selectively predispose to sarcomas.

Ballinger ML, Pattnaik S, Mundra PA, Zaheed M, Rath E, Priestley P, Baber J, Ray-Coquard I, Isambert N, Causeret S, van der Graaf WTA, Puri A, Duffaud F, Le Cesne A, Seddon B, Chandrasekar C, Schiffman JD, Brohl AS, James PA, Kurtz JE, Penel N, Myklebost O, Meza-Zepeda LA, Pickett H, Kansara M, Waddell N, Kondrashova O, Pearson JV, Barbour AP, Li S, Nguyen TL, Fatkin D, Graham RM, Giannoulatou E, Green MJ, Kaplan W, Ravishankar S, Copty J, Powell JE, Cuppen E, van Eijk K, Veldink J, Ahn JH, Kim JE, Randall RL, Tucker K, Judson I, Sarin R, Ludwig T, Genin E, Deleuze JF, ,Haber M, Marshall G, Cairns MJ, Blay JY, ,Thomas DM, Tattersall M, Neuhaus S, Lewis C, Tucker K, Carey-Smith R, Wood D, Porceddu S, Dickinson I, Thorne H, James P, Ray-Coquard I, Blay JY, Cassier P, Le Cesne A, Duffaud F, Penel N, Isambert N, Kurtz JE, Puri A, Sarin R, Ahn JH, Kim JE, Ward I, Judson I, van der Graaf W, Seddon B, Chandrasekar C, Rickar R, Hennig I, Schiffman J, Randall RL, Silvestri A, Zaratzian A, Tayao M, Walwyn K, Niedermayr E, Mang D, Clark R, Thorpe T, MacDonald J, Riddell K, Mar J, Fennelly V, Wicht A, Zielony B, Galligan E, Glavich G, Stoeckert J, Williams L, Djandjgava L, Buettner I, Osinki C, Stephens S, Rogasik M, Bouclier L, Girodet M, Charreton A, Fayet Y, Crasto S, Sandupatla B, Yoon Y, Je N, Thompson L, Fowler T, Johnson B, Petrikova G, Hambridge T, Hutchins A, Bottero D, Scanlon D, Stokes-Denson J, Génin E, Campion D, Dartigues JF, Deleuze JF, Lambert JC, Redon R, Ludwig T, Grenier-Boley B, Letort S, Lindenbaum P, Meyer V, Quenez O, Dina C, Bellenguez C, Le Clézio CC, Giemza J, Chatel S, Férec C, Le Marec H, Letenneur L, Nicolas G, Rouault K

Science. 2023 01 20;379(6629):253-260

Management and outcomes of adolescent and young adult sarcoma patients: results from the French nationwide database NETSARC.

Kubicek P, Cesne AL, Lervat C, Toulmonde M, Chevreau C, Duffaud F, Le Nail LR, Morelle M, Gaspar N, Vérité C, Castex MP, Penel N, Saada E, Causeret S, Bertucci F, Perrin C, Bompas E, Orbach D, Laurence V, Piperno-Neumann S, Anract P, Rios M, Gentet JC, Mascard É, Pannier S, Blouin P, Carrère S, Chaigneau L, Soibinet-Oudot P, Corradini N, Boudou-Rouquette P, Ruzic JC, Lebrun-Ly V, Dubray-Longeras P, Varatharajah S, Lebbe C, Ropars M, Kurtz JE, Guillemet C, Lotz JP, Berchoud J, Cherrier G, Ducimetière F, Chemin C, Italiano A, Honoré C, Desandes E, Blay JY, Gouin F, Marec-Bérard P

BMC Cancer. 2023 01 20;23(1):69

A propensity score-weighted study comparing a two- versus four-weekly pegylated liposomal doxorubicin regimen in metastatic breast cancer.

Bischoff H, Bigot C, Moinard-Butot F, Pflumio C, Fischbach C, Kalish M, Kurtz JE, Pierard L, Demarchi M, Karouby D, Coliat P, Pivot X, Petit T, Cox DG, Goepp L, Bender L, Trensz P

Breast Cancer Res Treat. 2022 12 23;:

Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.

Labidi-Galy SI, Rodrigues M, Sandoval JL, Kurtz JE, Heitz F, Mosconi AM, Romero I, Denison U, Nagao S, Vergote I, Parma G, Nøttrup TJ, Rouleau E, Garnier G, El-Balat A, Zamagni C, Martín-Lorente C, Pujade-Lauraine E, Fiévet A, Ray-Coquard IL

Ann Oncol. 2022 11 28;:

Shortening the Time Interval for the Referral of Patients With Soft Tissue Sarcoma to Expert Centers Using Mobile Health: Retrospective Study.

Nannini S, Penel N, Bompas E, Willaume T, Kurtz JE, Gantzer J

JMIR Mhealth Uhealth. 2022 11 9;10(11):e40718

Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial.

Pfisterer J, Joly F, Kristensen G, Rau J, Mahner S, Pautier P, El-Balat A, Kurtz JE, Canzler U, Sehouli J, Heubner ML, Hartkopf AD, Baumann K, Hasenburg A, Hanker LC, Belau A, Schmalfeldt B, Denschlag D, Park-Simon TW, Selle F, Jackisch C, Burges A, Lück HJ, Emons G, Meier W, Gropp-Meier M, Schröder W, de Gregorio N, Hilpert F, Harter P

J Clin Oncol. 2022 11 4;:JCO2201010

Association between recent pregnancy or hormonal contraceptive exposure and outcome of desmoid-type fibromatosis.

Debaudringhien M, Blay JY, Bimbai AM, Bonvalot S, Italiano A, Rousset-Jablonski C, Corradini N, Piperno-Neumann S, Chevreau C, Kurtz JE, Guillemet C, Bompas E, Collard O, Salas S, Le Cesne A, Orbach D, Thery J, Le Deley MC, Mir O, Penel N

ESMO Open. 2022 09 15;7(5):100578

[Practical management of PARP inhibitors: A French DELPHI consensus].

Selle F, Boffa JJ, Etienne G, Angelergues A, Augereau P, Berton D, Dielenseger P, Fabbro M, Falandry C, Follana P, Gladieff L, Joly F, Kurtz JE, Matta C, Mouret-Reynier MA, Schmitt A, Scotté F, Marjollet C, Floquet A

Bull Cancer. 2022 09 12;:

Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.

Vergote I, Gonzalez-Martin A, Lorusso D, Gourley C, Mirza MR, Kurtz JE, Okamoto A, Moore K, Kridelka F, McNeish I, Reuss A, Votan B, du Bois A, Mahner S, Ray-Coquard I, Kohn EC, Berek JS, Tan DSP, Colombo N, Zang R, Concin N, O'Donnell D, Rauh-Hain A, Herrington CS, Marth C, Poveda A, Fujiwara K, Stuart GCE, Oza AM, Bookman MA,

Lancet Oncol. 2022 08;23(8):e374-e384

Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study.

Joly F, Fabbro M, Berton D, Lequesne J, Anota A, Puszkiel A, Floquet A, Vegas H, Bourgeois H, Bengrine Lefevre L, You B, Pommeret F, Lortholary A, Spaeth D, Hardy-Bessard AC, Abdeddaim C, Kaminsky-Forrett MC, Tod M, Kurtz JE, Del Piano F, Meunier J, Raban N, Alexandre J, Mouret-Reynier MA, Ray-Coquard I, Provansal Gross M, Brachet PE

Gynecol Oncol. 2022 07 25;:

MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients.

Saint-Ghislain M, Derrien AC, Geoffrois L, Gastaud L, Lesimple T, Negrier S, Penel N, Kurtz JE, Le Corre Y, Dutriaux C, Gardrat S, Barnhill R, Matet A, Cassoux N, Houy A, Ramtohul T, Servois V, Mariani P, Piperno-Neumann S, Stern MH, Rodrigues M

Eur J Cancer. 2022 07 18;173:105-112

Lack of prognostic value of CTNNB1 mutation profile in desmoid-type fibromatosis.

Penel N, Bonvalot S, Bimbai AM, Meurgey A, Le Loarer F, Salas S, Piperno-Neumann S, Chevreau C, Boudou-Rouquette P, Dubray-Longeras P, Kurtz JE, Guillemet C, Bompas E, Italiano A, Le Cesne A, Orbach D, Thery J, Le Deley MC, Blay JY, Mir O

Clin Cancer Res. 2022 Mar 16;:

Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors.

Gantzer J, Davidson G, Vokshi B, Weingertner N, Bougoüin A, Moreira M, Lindner V, Lacroix G, Mascaux C, Chenard MP, Bertucci F, Davidson I, Kurtz JE, Sautès-Fridman C, Fridman WH, Malouf GG

Oncologist. 2022 Mar 12;:

Sporadic Desmoid Tumours: Systematic Review with Reflection on the Role of Cryoablation.

Cazzato RL, Gantzer J, de Marini P, Garnon J, Koch G, Buy X, Autrusseau PA, Auloge P, Dalili D, Kurtz JE, Gangi A

Cardiovasc Intervent Radiol. 2022 Mar 2;:

Liver-Directed Therapy for Neuroendocrine Metastases: From Interventional Radiology to Nuclear Medicine Procedures.

Cazzato RL, Hubelé F, De Marini P, Ouvrard E, Salvadori J, Addeo P, Garnon J, Kurtz JE, Greget M, Mertz L, Goichot B, Gangi A, Imperiale A

Cancers (Basel). 2021 Dec 19;13(24):

Prise en charge médicale de la récidive du cancer épithélial de l'ovaire: Medical management of recurrent epithelial ovarian cancer.

Pautier P, Motte-Rouge T, Lécuru F, Classe JM, Ferron G, Floquet A, Kurtz JE, Freyer G, Hardy-Bessard AC

Bull Cancer. 2021 Dec;108(9S1):S22-S32

[Sar'connect a mobile app to enhance soft-tissue sarcoma patients' referral to expert centers].

Nannini S, Gantzer J, Tetreau R, Blay JY, Kurtz JE

Bull Cancer. 2021 Oct 28;:

"Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tu

Gernier F, Ahmed-Lecheheb D, Pautier P, Floquet A, Nadeau C, Frank S, Alexandre J, Selle F, Berton-Rigaud D, Kalbacher E, Orfeuvre H, Lortholary A, Augereau P, Labombarda F, Perrier L, Grellard JM, Licaj I, Clarisse B, Savoye AM, Bourien H, De La Motte Rouge T, Kurtz JE, Kerdja K, Lelaidier A, Charreton A, Ray-Coquard I, Joly F

BMC Cancer. 2021 Oct 26;21(1):1147

Natural History and Treatment Strategies of Advanced PEComas: A Systematic Review.

Bourgmayer A, Nannini S, Bonjean P, Kurtz JE, Malouf GG, Gantzer J

Cancers (Basel). 2021 Oct 18;13(20):

Rare bone sarcomas: a retrospective analysis of 145 adult patients from the French Sarcoma Group.

Boudou-Rouquette P, Martin E, Kempf E, Penel N, Toulmonde M, Bompas E, Duffaud F, Firmin N, Bertucci F, Kurtz JE, Chaigneau L, Isambert N, Saada-Bouzid E, Dubray-Longeras P, Larousserie F, Anract P, Chevreau C, Blay JY, Piperno-Neumann S,

Int J Cancer. 2021 Oct 6;:

Treatment of 120 adult osteosarcoma patients with metachronous and synchronous metastases: a retrospective series of the French Sarcoma Group.

Lavit E, Aldea M, Piperno-Neumann S, Firmin N, Italiano A, Isambert N, Kurtz JE, Delcambre C, Lebrun V, Soibinet-Oudot P, Chevreau C, Bompas E, Le Maignan C, Boudou-Rouquette P, Le Cesne A, Mancini J, Blay JY, Duffaud F

Int J Cancer. 2021 Sep 25;:

Survival and Predictive Factors of Chemotherapy With FOLFIRINOX as First-Line Therapy in Metastatic Pancreatic Cancer: A Retrospective Multicentric Analysis.

Caron B, Reimund JM, Ben Abdelghani M, Sondag D, Noirclerc M, Duclos B, Kurtz JE, Nguimpi-Tambou M

Pancreas. 2021 Aug 3;:

Involvement of Neutrophils in Metastatic Evolution of Pancreatic Neuroendocrine Tumors.

Debien V, Davidson G, Baltzinger P, Kurtz JE, Séverac F, Imperiale A, Pessaux P, Addeo P, Bachellier P, Su X, Davidson I, Chenard MP, Goichot B, Malouf GG

Cancers (Basel). 2021 Jun 2;13(11):

Joint IARC/NCI International Cancer Seminar Series Report: Expert consensus on future directions for ovarian carcinoma research.

Virani S, Baiocchi G, Bowtell D, Cabasag CJ, Cho KR, Fortner RT, Fujiwara K, Kim JW, Köbel M, Kurtz JE, Levine DA, Menon U, Norquist BM, Pharoah PDP, Sood AK, Tworoger ST, Wentzensen N, Chanock SJ, Brennan P, Trabert B

Carcinogenesis. 2021 May 25;:

COVID-19 in cancer patients: A retrospective study of 212 cases from a French SARS-CoV-2 cluster during the first wave of the COVID-19 pandemic.

Martin S, Kaeuffer C, Leyendecker P, Tuzin N, Tazi Y, Schaff-Wendling F, Kleinheny T, Husson-Wetzel S, Pamart G, Limacher JM, Clerc O, Dicop E, Kurtz JE, Barthélémy P, Gantzer J

Oncologist. 2021 May 24;:

18F-FDG PET/CT Monitoring of Tumor Response to Tyrosine Kinase Inhibitors and Alkylating Drugs in an SDH-Deficient GIST.

Somme F, Bender L, Kurtz JE, Gantzer J, Imperiale A

Clin Nucl Med. 2021 Mar 16;:

Percutaneous cryoablation for advanced and refractory extra-abdominal desmoid tumors.

Auloge P, Garnon J, Robinson JM, Thenint MA, Koch G, Caudrelier J, Weiss J, Cazzato RL, Kurtz JE, Gangi A

Int J Clin Oncol. 2021 Mar 11;:

Isoforms of the p53 Family and Gastric Cancer: A Ménage à Trois for an Unfinished Affair.

Blanchet A, Bourgmayer A, Kurtz JE, Mellitzer G, Gaiddon C

Cancers (Basel). 2021 Feb 22;13(4):

Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee.

Kurtz JE, Gebski V, Sukhin V, Carey M, Kong I, Glasspool RM, Berek JS, de Paiva Batista M, Hall M, Kim JW, Yeoshoua E, Fujiwara N, Nam BH, Polleis S, Lee JY, Strojna A, Farrelly L, Schwameis R, Fossati R, Darlington AS, Lai CH, Wright AA, Rosenblat O, Harter P, Roxburgh P, Chowdhury RR, Chang TC, Paoletti X, Friedlander M,

Gynecol Oncol. 2021 Feb 18;:

Intravenous and subcutaneous administration of trastuzumab in a patient on peritoneal dialysis.

Kokkali S, Ternant D, Kemmel V, Levêque D, Wendling F, Barthelemy P, Kurtz JE

Br J Clin Pharmacol. 2021 Jan 19;:

CRYODESMO-O1: A prospective, open phase II study of cryoablation in desmoid tumour patients progressing after medical treatment.

Kurtz JE, Buy X, Deschamps F, Sauleau E, Bouhamama A, Toulmonde M, Honoré C, Bertucci F, Brahmi M, Chevreau C, Duffaud F, Gantzer J, Garnon J, Blay JY, Gangi A

Eur J Cancer. 2020 Dec 5;143:78-87

Adjuvant Trastuzumab Is Required in Human Epidermal Growth Factor Receptor 2-Positive Node-Negative Breast Cancer Patients Regardless of Tumour Size.

Bender L, Kurtz JE, Petit T, Pivot X

J Breast Cancer. 2020 Dec;23(6):672-673

French Multidisciplinary Approach for the Treatment of MSK Tumors.

Cazzato RL, Garnon J, De Marini P, Auloge P, Dalili D, Koch G, Antoni D, Barthelemy P, Kurtz JE, Malouf G, Feydy A, Charles YP, Gangi A

Semin Musculoskelet Radiol. 2020 Jun;24(3):310-322

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.

Pfisterer J, Shannon CM, Baumann K, Rau J, Harter P, Joly F, Sehouli J, Canzler U, Schmalfeldt B, Dean AP, Hein A, Zeimet AG, Hanker LC, Petit T, Marmé F, El-Balat A, Glasspool R, de Gregorio N, Mahner S, Meniawy TM, Park-Simon TW, Mouret-Reynier MA, Costan C, Meier W, Reinthaller A, Goh JC, L'Haridon T, Baron Hay S, Kommoss S, du Bois A, Kurtz JE,

Lancet Oncol.. 2020 Apr 16;:

CA-125 ELIMination rate constant K (KELIM) Is A Marker Of Chemosensitivity In Patients With Ovarian Cancer: Results from the Phase II CHIVA trial.

You B, Robelin P, Tod M, Louvet C, Lotz JP, Abadie-Lacourtoisie S, Fabbro M, Desauw C, Bonichon-Lamichhane N, Kurtz JE, Follana P, Leheurteur M, Del Piano F, Ferron G, DE Rauglaudre G, Ray-Coquard I, Combe P, Chevalier Place A, Joly F, Leary A, Pujade-Lauraine E, Freyer G, Colomban O

Clin. Cancer Res.. 2020 Mar 24;:

Successful treatment of primary cutaneous angiosarcoma of the nose with sequential chemo- and radiotherapy.

Herrscher H, Bronnec M, Antoni D, Ghnassia JP, Magnenet P, Kurtz JE, Noël G

Clin Transl Radiat Oncol. 2020 Mar;21:1-4

Complete Response of a Pleural, Hepatic, and Splenic Metastatic Primary Breast Angiosarcoma Using Gemcitabine Monotherapy.

Bender L, Gantzer J, Somme F, Weingertner N, Kurtz JE

JCO Oncol Pract. 2020 Feb 18;:JOP1900609

[MiT family translocation renal cell carcinomas: Natural history, molecular features and multidisciplinary management].

Herrscher H, Boilève A, Lindner V, Barthélémy P, Hutt É, Pierard L, Kurtz JE, Rioux-Leclercq N, Lang H, Malouf GG

Bull Cancer. 2020 Feb 7;:

[Loco-regional therapy for desmoid tumeurs. Current status and perspectives].

Kurtz JE, Gantzer J, Garnon J, Gangi A

Bull Cancer. 2019 Dec 24;:

Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancers.

Rousset-Jablonski C, Selle F, Adda-Herzog E, Planchamp F, Selleret L, Pomel C, Daraï E, Chabbert-Buffet N, Pautier P, Trémollières F, Guyon F, Rouzier R, Laurence V, Chopin N, Faure-Conter C, Bentivegna E, Vacher-Lavenu MC, Lhomme C, Floquet A, Treilleux I, Lecuru F, Gouy S, Kalbacher E, Genestie C, Thibault MR, Ferron G, Devouassoux M, Kurtz JE, Provansal M, Namer M, Joly F, Pujade-Lauraine E, Grynberg M, Querleu D, Morice P, Gompel A, Ray-Coquard I

Eur. J. Cancer. 2019 Jun 3;116:35-44

Conformity to Clinical Practice Guidelines at Initial Management in Adult Soft Tissue and Visceral Tumors since the Implementation of the NetSarc Network in Eastern France.

Gantzer J, Di Marco A, Fabacher T, Weingertner N, Delhorme JB, Brinkert D, Bierry G, Ghnassia JP, Jégu J, Kurtz JE

Oncologist. 2019 May 9;:

Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study.

Joly F, Ahmed-Lecheheb D, Kalbacher E, Heutte N, Clarisse B, Grellard JM, Gernier F, Berton-Rigaud D, Tredan O, Fabbro M, Savoye AM, Kurtz JE, Alexandre J, Follana P, Delecroix V, Dohollou N, Roemer-Becuwe C, De Rauglaudre G, Lortholary A, Prulhiere K, Lesoin A, Zannetti A, N'Guyen S, Trager-Maury S, Chauvenet L, Abadie Lacourtoisie S, Gompel A, Lhommé C, Floquet A, Pautier P

Ann. Oncol.. 2019 May;30(5):845-852

Intensive care for patients with gastric cancers: outcome and survival prognostic factors.

Herrscher H, Artzner T, Severac F, Faitot F, Kurtz JE, Janssen-Langenstein R, Maestraggi Q, Schneider F, Michard B

J Gastrointest Oncol. 2019 Apr;10(2):292-299

Sarcomas in patients over 90: natural history and treatment. A nationwide study over 6 years.

Basse C, Italiano A, Penel N, Mir O, Chemin C, Toulmonde M, Duffaud F, Le Cesne A, Chevreau C, Maynou C, Anract P, Gouin F, Rios M, Firmin N, Kurtz JE, Kerbrat P, Piperno-Neumann S, Bertucci F, Rosset P, Isambert N, Bompas E, Dubray-Longeras P, Fiorenza F, Le Maignan C, Chaigneau L, Thyss A, Bouché O, Eymard JC, Lair CD, Adam J, Karanian M, Lebbé C, Dupré A, Meeus P, Brahmi M, Dufresne A, Ducimetière F, Ray-Coquard I, Blay JY

Int. J. Cancer. 2019 Mar 28;:

Long-term fatigue and quality of life among epithelial ovarian cancer survivors: A GINECO case/control VIVROVAIRE I Study.

Joly F, Ahmed-Lecheheb D, Kalbacher E, Heutte N, Clarisse B, Grellard JM, Gernier F, Berton-Rigaud D, Tredan O, Fabbro M, Savoye AM, Kurtz JE, Alexandre J, Follana P, Delecroix V, Dohollou N, Roemer-Becuwe C, De Rauglaudre G, Lortholary A, Prulhiere K, Lesoin A, Zannetti A, N'Guyen S, Trager-Maury S, Chauvenet L, Abadie Lacourtoisie S, Gompel A, Lhommé C, Floquet A, Pautier P

Ann. Oncol.. 2019 Mar 9;:

Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study.

Edeline J, Benabdelghani M, Bertaut A, Watelet J, Hammel P, Joly JP, Boudjema K, Fartoux L, Bouhier-Leporrier K, Jouve JL, Faroux R, Guerin-Meyer V, Kurtz JE, Assénat E, Seitz JF, Baumgaertner I, Tougeron D, de la Fouchardière C, Lombard-Bohas C, Boucher E, Stanbury T, Louvet C, Malka D, Phelip JM

J. Clin. Oncol.. 2019 Feb 1;:JCO1800050

Brain Metastases and Place of Antiangiogenic Therapies in Alveolar Soft Part Sarcoma: A Retrospective Analysis of the French Sarcoma Group.

Malouf GG, Beinse G, Adam J, Mir O, Chamseddine AN, Terrier P, Honore C, Spano JP, Italiano A, Kurtz JE, Coindre JM, Blay JY, Le Cesne A

Oncologist. 2019 Jan 9;:

Integrated Multi-omic Analysis of Esthesioneuroblastomas Identifies Two Subgroups Linked to Cell Ontogeny.

Classe M, Yao H, Mouawad R, Creighton CJ, Burgess A, Allanic F, Wassef M, Leroy X, Verillaud B, Mortuaire G, Bielle F, Le Tourneau C, Kurtz JE, Khayat D, Su X, Malouf GG

Cell Rep. 2018 Oct 16;25(3):811-821.e5

Carboplatin/pegylated liposomal doxorubicin/bevacizumab (CD-BEV) vs. carboplatin/gemcitabine/bevacizumab (CG-BEV) in patients with recurrent ovarian cancer: A prospective randomized phase III ENGOT/GCIG-Intergroup study (AGO study group, AGO-Austria, ANZG

Pfisterer J, Dean AP, Baumann K, Rau J, Harter P, Joly F, Sehouli J, Canzler U, Schmalfeldt B, Shannon C, Hein A, Reimer DU, Hanker LC, Petit T, Marmé F, El-Balat A, Glasspool R, de Gregorio N, Mahner S, Kurtz JE

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii332-viii333

Natural history of sarcomas and impact of reference centers in the nationwide NETSARC study on 35,784 patients (pts) from 2010 to 2017.

Blay JY, Toulmonde M, Penel N, Mir O, Chevreau CM, Anract P, Bompas E, Rios M, Firmin N, Italiano A, Piperno-Neumann S, Kurtz JE, Duffaud F, Rosset P, Bertucci F, Perrin C, Chemin C, Ducimetiere F, Gouin F, Le Cesne A

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii576

Metabolic Response to BRAF-MEK Combination Therapy in Cecal Neuroendocrine Carcinoma With BRAFV600E Mutation and Refractory Lactic Acidosis.

Imperiale A, Latgé A, Schaff-Wendling F, Goichot B, Kurtz JE, Malouf GG

Clin Nucl Med. 2018 Jul 21;:

Outcome of 449 adult patients with rhabdomyosarcoma: an observational ambispective nationwide study.

Bompas E, Campion L, Italiano A, Le Cesne A, Chevreau C, Isambert N, Toulmonde M, Mir O, Ray-Coquard I, Piperno-Neumann S, Saada-Bouzid E, Rios M, Kurtz JE, Delcambre C, Dubray-Longeras P, Duffaud F, Karanian M, Le Loarer F, Soulié P, Penel N, Blay JY

Cancer Med. 2018 Jun 28;:

Cognitive Changes After Adjuvant Treatment in Older Adults with Early-Stage Breast Cancer.

Lange M, Heutte N, Noal S, Rigal O, Kurtz JE, Lévy C, Allouache D, Rieux C, Lefel J, Clarisse B, Leconte A, Veyret C, Barthélémy P, Longato N, Tron L, Castel H, Eustache F, Giffard B, Joly F

Oncologist. 2018 Jun 22;:

The hard road to patient-centered care: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?

Trensz P, Calvel L, Kurtz JE

Ann. Oncol.. 2018 May 22;:

Sexual Disorders of Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Antiangiogenic Therapies.

Denouel A, Heutte N, Escudier B, Kurtz JE, Santos MD, Longato N, Desrues L, Dauchy S, Lange M, Sevin E, Rieux C, Clarisse B, Castel H, Noal S, Joly F

Clin Genitourin Cancer. 2018 May 21;:

[Expectation about maintenance therapy among the GINECO French ovarian cancer cohort from the European NOGGO/ENGOT-ov22 Expression IV survey].

Lorcet M, Lortholary A, Kurtz JE, Berton-Rigaud D, Fabbro M, De La Motte Rouge T, Kaminsky-Forrett MC, Floquet A, Freyer G, Combe P, Dohollou N, Kalbacher E, Despax R, Largillier R, Hardy Bessard AC, Gane N, Sehouli J, Oskay-Oezcelik G, Licaj I, Ray-Coquard I, Joly Lobbedez F

Bull Cancer. 2018 May;105(5):465-474

Expression III: patients' expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries.

Oskay-Özcelik G, Alavi S, Richter R, Keller M, Chekerov R, Cecere SC, Cormio G, Joly F, Kurtz JE, du Bois A, Maciejewski M, Jedryka M, Vergote I, Van Nieuwenhuysen E, Casado A, Mendiola C, Achimas-Cadariu P, Vlad C, Reimer D, Zeimet AG, Friedlander M, Sehouli J

Ann. Oncol.. 2018 Apr 1;29(4):910-916

Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study.

Walter T, Malka D, Hentic O, Lombard-Bohas C, Le Malicot K, Smith D, Ferru A, Assenat E, Cadiot G, Lievre A, Kurtz JE, Dahan L, Dubreuil O, Hautefeuille V, Lepere C, Gangloff A, Elhajbi F, Coriat R, Roquin G, Bouarioua N, Granger V, Scoazec JY, Lepage C

Dig Liver Dis. 2018 Feb;50(2):195-198

Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.

Korenbaum C, Pierard L, Thiéry A, Story F, Lindner V, Lang H, Kurtz JE, Barthélémy P

Clin Genitourin Cancer. 2017 Dec 28;:

Improved survival using specialized multidisciplinary board in sarcoma patients.

Blay JY, Soibinet P, Penel N, Bompas E, Duffaud F, Stoeckle E, Mir O, Adam J, Chevreau C, Bonvalot S, Rios M, Kerbrat P, Cupissol D, Anract P, Gouin F, Kurtz JE, Lebbe C, Isambert N, Bertucci F, Toumonde M, Thyss A, Piperno-Neumann S, Dubray-Longeras P, Meeus P, Ducimetière F, Giraud A, Coindre JM, Ray-Coquard I, Italiano A, Le Cesne A,

Ann. Oncol.. 2017 Nov 1;28(11):2852-2859

Dual effects of constitutively active androgen receptor and full-length androgen receptor for N-cadherin regulation in prostate cancer.

Cottard F, Madi-Berthélémy PO, Erdmann E, Schaff-Wendling F, Keime C, Ye T, Kurtz JE, Céraline J

Oncotarget. 2017 Sep 22;8(42):72008-72020

Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group.

Penel N, Le Cesne A, Bonvalot S, Giraud A, Bompas E, Rios M, Salas S, Isambert N, Boudou-Rouquette P, Honore C, Italiano A, Ray-Coquard I, Piperno-Neumann S, Gouin F, Bertucci F, Ryckewaert T, Kurtz JE, Ducimetiere F, Coindre JM, Blay JY

Eur. J. Cancer. 2017 Jul;83:125-131

Kurtz JE, D'Hondt V, Lécuru F, Lhommé C

Bull Cancer. 2017 May;104 Suppl 1:S39-S42

Dual effects of constitutively active androgen receptor and full-length androgen receptor for N-cadherin regulation in prostate cancer.

Cottard F, Ould Madi-Berthélémy P, Erdmann E, Schaff-Wendling F, Keime C, Ye T, Kurtz JE, Céraline J

Oncotarget. 2017 May;:

Medical treatment of mammary desmoid-type fibromatosis: which benefit?

Scheer L, Lodi M, Molière S, Kurtz JE, Mathelin C

World J Surg Oncol. 2017 Apr;15(1):86

Networking for ovarian rare tumors: a significant breakthrough improving disease management.

Chiannilkulchai N, Pautier P, Genestie C, Bats AS, Vacher-Lavenu MC, Devouassoux-Shisheboran M, Treilleux I, Floquet A, Croce S, Ferron G, Mery E, Pomel C, Penault-Llorca F, Lefeuvre-Plesse C, Henno S, Leblanc E, Lemaire AS, Averous G, Kurtz JE, Ray-Coquard I

Ann. Oncol.. 2017 Apr;:

Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine.

Husseini F, Delord JP, Fournel-Federico C, Guitton J, Erbs P, Homerin M, Halluard C, Jemming C, Orange C, Limacher JM, Kurtz JE

Ann. Oncol.. 2017 Jan;28(1):169-174

Adrenal Metastasis of a Poorly Differentiated Adenocarcinoma Mimicking a Pheochromocytoma on 18F-FDOPA PET/CT.

Heimburger C, Averous G, Charlin E, Lang H, Kurtz JE, Imperiale A

Clin Nucl Med. 2016 Sep;41(9):691-2

Vectorized Gene Therapy of Liver Tumors: Proof of Concept of TG4023 (MVA-FCU1) in Combination with Flucytosine.

Husseini F, Delord JP, Fournel-Federico C, Guitton J, Erbs P, Homerin M, Halluard C, Jemming C, Orange C, Limacher JM, Kurtz JE

Ann. Oncol.. 2016 Sep;:

Decline in Cognitive Function in Older Adults With Early-Stage Breast Cancer After Adjuvant Treatment.

Lange M, Heutte N, Rigal O, Noal S, Kurtz JE, Lévy C, Allouache D, Rieux C, Lefel J, Clarisse B, Veyret C, Barthélémy P, Longato N, Castel H, Eustache F, Giffard B, Joly F

Oncologist. 2016 Jul;:

"Hockey Stick" may Strike Back: Hepatocellular Carcinoma on Noncirrhotic Liver as a Late Toxicity of Lombo-Aortic Radiotherapy for Seminoma. A Review Triggered by an Unusual Case.

Korenbaum C, Barthelemy P, Onea A, Salze P, Kurtz JE

J Clin Exp Hepatol. 2016 Mar;6(1):54-8

Biosimilar epoetin for the management of chemotherapy-induced anemia in elderly patients.

Kurtz JE, Soubeyran P, Michallet M, Luporsi E, Albrand H

Onco Targets Ther. 2016 ;9:6689-6693

Does the Number of Neoadjuvant Chemotherapy Cycles before Interval Debulking Surgery Influence Survival in Advanced Ovarian Cancer?

Akladios C, Baldauf JJ, Marchal F, Hummel M, Rebstock LE, Kurtz JE, Petit T, Afors K, Mathelin C, Lecointre L, Schrot-Sanyan S

Oncology. 2016 ;91(6):331-340

Gene expression profiling of desmoid tumors by cDNA microarrays and correlation with Progression-Free survival.

Salas S, Brulard C, Terrier P, Ranchere-Vince D, Mechine-Neuville A, Guillou L, Lae M, Leroux A, Verola O, Kurtz JE, Bonvalot S, Blay JY, Le Cesne A, Aurias A, Coindre JM, Chibon F

Clin Cancer Res. 2015 Apr 15. pii: clincanres.2910.2014.

Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group.

Le Cesne A, Ray-Coquard I, Duffaud F, Chevreau C, Penel N, Bui Nguyen B, Piperno-Neumann S, Delcambre C, Rios M, Chaigneau L, Le Maignan C, Guillemet C, Bertucci F, Bompas E, Linassier C, Olivier T, Kurtz JE, Even C, Cousin P, Yves Blay J

Eur J Cancer. 2015 Apr;51(6):742-50

[Expectations of patients with ovarian cancer. Results of the European investigation EXPRESSION III in French patients from GINECO group].

De Cock L, Kieffer A, Kurtz JE, Joly F, Weber B

Bull Cancer. 2015 Mar;102(3):217-25

Adherence and patients' attitudes to oral anticancer drugs: a prospective series of 201 patients focusing on targeted therapies.

Barthelemy P, Asmane-De la Porte I, Meyer N, Duclos B, Serra S, Dourthe LM, Ame S, Litique V, Giron C, Goldbarg V, Fornecker L, Quoix E, Kurtz JE

Oncology. 2015;88(1):1-8

Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.

Mitry E, Walter T, Baudin E, Kurtz JE, Ruszniewski P, Dominguez-Tinajero S, Bengrine-Lefevre L, Cadiot G, Dromain C, Farace F, Rougier P, Ducreux M

Eur. J. Cancer. 2014 Dec;50(18):3107-15

Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma.

Sagae S, Susumu N, Viswanathan AN, Aoki D, Backes FJ, Provencher DM, Vaughan M, Creutzberg CL, Kurzeder C, Kristensen G, Lee C, Kurtz JE, Glasspool RM, Small W Jr

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S83-9

Baseline cognitive functions among elderly patients with localised breast cancer.

Lange M, Giffard B, Noal S, Rigal O, Kurtz JE, Heutte N, Levy C, Allouache D, Rieux C, Le Fel J, Daireaux A, Clarisse B, Veyret C, Barthelemy P, Longato N, Eustache F, Joly F

Eur J Cancer. 2014 Sep;50(13):2181-9

Baseline nutritional status is prognostic factor after definitive radiochemotherapy for esophageal cancer.

Clavier JB, Antoni D, Atlani D, Ben Abdelghani M, Schumacher C, Dufour P, Kurtz JE, Noel G

Dis Esophagus. 2014 Aug;27(6):560-7

Pertuzumab: development beyond breast cancer.

Barthelemy P, Leblanc J, Goldbarg V, Wendling F, Kurtz JE

Anticancer Res. 2014 Apr;34(4):1483-91.

18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation.

Imperiale A, Rust E, Gabriel S, Detour J, Goichot B, Duclos B, Kurtz JE, Bachellier P, Namer IJ, Taieb D

J Nucl Med. 2014 Mar;55(3):367-72

Age impacts the pattern of care for elderly patients with rectal cancer.

Guillerme F, Clavier JB, Nehme-Schuster H, Leroy V, Heitz D, Schumacher C, Abdelghani MB, Brigand C, Kurtz JE, Noel G

Int J Colorectal Dis. 2014 Feb;29(2):157-63

Primary cardiac sarcomas: a retrospective study of the French Sarcoma Group.

Isambert N, Ray-Coquard I, Italiano A, Rios M, Kerbrat P, Gauthier M, Blouet A, Chaigneau L, Duffaud F, Piperno-Neumann S, Kurtz JE, Girard N, Collard O, Bompas E, Penel N, Bay JO, Guillemet C, Collin F, Blay JY, Le Cesne A, Thariat J

Eur J Cancer. 2014 Jan;50(1):128-36

Screening for Vulnerability in Older Cancer Patients: The ONCODAGE Prospective Multicenter Cohort Study.

Soubeyran P, Bellera C, Goyard J, Heitz D, Cure H, Rousselot H, Albrand G, Servent V, Jean OS, van Praagh I, Kurtz JE, Perin S, Verhaeghe JL, Terret C, Desauw C, Girre V, Mertens C, Mathoulin-Pelissier S, Rainfray M

PLoS One. 2014 Dec 11;9(12):e115060

Advanced chondrosarcomas: role of chemotherapy and survival.

Italiano A, Mir O, Cioffi A, Palmerini E, Piperno-Neumann S, Perrin C, Chaigneau L, Penel N, Duffaud F, Kurtz JE, Collard O, Bertucci F, Bompas E, Le Cesne A, Maki RG, Ray Coquard I, Blay JY

Ann Oncol. 2013 Nov;24(11):2916-22

Osteosarcomas of the mandible: multidisciplinary management of a rare tumor of the young adult a cooperative study of the GSF-GETO, Rare Cancer Network, GETTEC/REFCOR and SFCE.

Thariat J, Schouman T, Brouchet A, Sarini J, Miller RC, Reychler H, Ray-Coquard I, Italiano A, Verite C, Sohawon S, Bompas E, Dassonville O, Salas S, Aldabbagh K, Maingon P, de La MotteRouge T, Kurtz JE, Usseglio J, Kerbrat P, Raoul G, Lotz JP, Bar-Sela G, Brugieres L, Chaigneau L, Saada E, Odin G, Marcy PY, Thyss A, Julieron M

Ann Oncol. 2013 Mar;24(3):824-31

Constitutively active androgen receptor variants upregulate expression of mesenchymal markers in prostate cancer cells.

Cottard F, Asmane I, Erdmann E, Bergerat JP, Kurtz JE, Ceraline J

PLoS One. 2013 May 2;8(5):e63466

Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.

Asmane I, Watkin E, Alberti L, Duc A, Marec-Berard P, Ray-Coquard I, Cassier P, Decouvelaere AV, Ranchere D, Kurtz JE, Bergerat JP, Blay JY

Eur J Cancer. 2012 Nov;48(16):3027-35

PI3 kinase inhibitors in the clinic: an update.

Kurtz JE, Ray-Coquard I

Anticancer Res. 2012 Jul;32(7):2463-70.

Role of FDOPA PET/CT imaging and conventional imaging in the management of patients with endocrine tumor of unknown origin.

Rust E, Goichot B, Kurtz JE, Pessaux P, Imperiale A

. 2012 May;36(5):278-90.

Combined oral topotecan plus carboplatin in relapsed or advanced cervical cancer: a GINECO phase I-II trial.

Kurtz JE, Freyer G, Joly F, Gladieff L, Kaminski MC, Fabbro M, Floquet A, Hardy-Bessard AC, Raban N, Ray-Coquard I, Pujade-Lauraine E

Anticancer Res. 2012 Mar;32(3):1045-9.

Nuclear medicine imaging of gastro-entero-pancreatic neuroendocrine tumors. The key role of cellular differentiation and tumor grade: from theory to clinical practice.

Rust E, Hubele F, Marzano E, Goichot B, Pessaux P, Kurtz JE, Imperiale A

Cancer Imaging. 2012 May 21;12:173-84

Evolving standards of care in advanced gastric cancer.

Kurtz JE, Dufour P

Future Oncol. 2011 Dec;7(12):1441-50.

Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study.

Kurtz JE, Kaminsky MC, Floquet A, Veillard AS, Kimmig R, Dorum A, Elit L, Buck M, Petru E, Reed N, Scambia G, Varsellona N, Brown C, Pujade-Lauraine E

Ann Oncol. 2011 Nov;22(11):2417-23

Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study.

Asmane I, Kurtz JE, Bajard A, Guastalla JP, Meeus P, Tredan O, Labidi Galy I, Moullet I, Ardisson P, Vincent L, Coeffic D, Dufresne A, Bergerat JP, Ray-Coquard I

Bull Cancer. 2011 Oct 1;98(9):80-9

Adjuvant chemotherapy in elderly patients with early breast cancer. Impact of age and comprehensive geriatric assessment on tumor board proposals.

Barthelemy P, Heitz D, Mathelin C, Polesi H, Asmane I, Litique V, Rob L, Bergerat JP, Kurtz JE

Crit Rev Oncol Hematol. 2011 Aug;79(2):196-204

New strategies for medical management of castration-resistant prostate cancer.

Asmane I, Ceraline J, Duclos B, Rob L, Litique V, Barthelemy P, Bergerat JP, Dufour P, Kurtz JE

Oncology. 2011;80(1-2):1-11

Geriatric oncology, general practitioners and specialists: current opinions and unmet needs.

Kurtz JE, Heitz D, Enderlin P, Imbert F, Nehme H, Bergerat JP, Dufour P

Crit Rev Oncol Hematol. 2010 Jul;75(1):47-57

Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside.

Kurtz JE, Dufour P

Expert Opin Biol Ther. 2010 Jun;10(6):951-8.

Adjuvant chemotherapy in elderly patients with colorectal cancer. A retrospective analysis of the implementation of tumor board recommendations in a single institution.

Kurtz JE, Heitz D, Serra S, Brigand C, Juif V, Podelski V, Meyer P, Litique V, Bergerat JP, Rohr S, Dufour P

Crit Rev Oncol Hematol. 2010 Jun;74(3):211-7

Phase I study of irinotecan and cisplatin in combination with pelvic radiotherapy in the treatment of locally advanced cervical cancer: A GINECO trial.

Fabbro M, Gladieff L, Guichard F, El Demery M, Dalenc F, Kerr C, Delannes M, Paraiso D, Pujade-Lauraine E, Kurtz JE

Gynecol Oncol. 2010 May;117(2):276-80

A V530I Mutation in c-KIT Exon 10 Is Associated to Imatinib Response in Extraabdominal Aggressive Fibromatosis.

Kurtz JE, Asmane I, Voegeli AC, Neuville A, Dufresne A, Litique V, Chevreau C, Bergerat JP

Sarcoma. 2010;2010:458156

Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line.

Marcias G, Erdmann E, Lapouge G, Siebert C, Barthelemy P, Duclos B, Bergerat JP, Ceraline J, Kurtz JE

Hum Mutat. 2010 Jan;31(1):74-80.

Emergency management of a particular massive pulmonary embolism...

Talha S, Cohen C, Kindo M, Asmane I, Faure A, Eisenmann B, Geny B, Kurtz JE

J Card Surg. 2009 Jul-Aug;24(4):472-4

Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial.

Kurtz JE, Hardy-Bessard AC, Deslandres M, Lavau-Denes S, Largillier R, Roemer-Becuwe C, Weber B, Guillemet C, Paraiso D, Pujade-Lauraine E

Gynecol Oncol. 2009 Apr;113(1):16-20

[Primary myeloid sarcoma of uterine cervix and prevention of fertility. Report of a case]

Prados E, Garbin O, Kurtz JE

Gynecol Obstet Fertil. 2009 Mar;37(3):265-8

Geriatric oncology: how far have we gone and what are the next steps?

Kurtz JE, Heitz D, Kurtz-Illig V, Dufour P

Oncology. 2009;77(3-4):147-56

Adriamycin, Cisplatin, Ifosfamide and Paclitaxel Combination as Front-line Chemotherapy for Locally Advanced and Metastatic Angiosarcoma. Analysis of Three Case Reports and Review of the Literature

Asmane I, Litique V, Heymann S, Marcellin L, Metivier AC, Duclos B, Bergerat JP, Kurtz JE

Anticancer Res. 2008 Sep-Oct;28(5B):3041-5.

Late outcome of 89 patients with soft-tissue sarcomas treated by surgery and three different radiotherapy schedules

Heymanna S, Jung GM, Simon P, Bergerat JP, Borel C, Di Marco A, Kurtz JE, Marcellin L, Ghnassia JP, Dufour P, Noel G

Cancer Radiother. 2007 Dec;11(8):443-51

Phase II trial of pegylated liposomal doxorubicin-cyclophosphamide combination as first-line chemotherapy in older metastatic breast cancer patients.

Kurtz JE, Rousseau F, Meyer N, Delozier T, Serin D, Nabet M, Djafari L, Dufour P

Oncology. 2007;73(3-4):210-4

Food-cobalamin malabsorption in elderly patients: clinical manifestations and treatment.

Andres E, Affenberger S, Vinzio S, Kurtz JE, Noel E, Kaltenbach G, Maloisel F, Schlienger JL, Blickle JF

Am J Med. 2005 Oct;118(10):1154-9.

Constitutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgen-independent growth in prostate cancer.

Ceraline J, Cruchant MD, Erdmann E, Erbs P, Kurtz JE, Duclos B, Jacqmin D, Chopin D, Bergerat JP

Int J Cancer. 2004 Jan 1;108(1):152-7.

Diffuse primary angiosarcoma of the pleura: a case report and review of the literature.

Kurtz JE, Serra S, Duclos B, Brolly F, Dufour P, Bergerat JP

Sarcoma. 2004;8(4):103-6.

A phase II study of docetaxel-irinotecan combination in advanced pancreatic cancer.

Kurtz JE, Negrier S, Husseini F, Limacher JM, Borel C, Wagner JP, Prevot G, Bergerat JP, Dufour P

Hepatogastroenterology. 2003 Mar-Apr;50(50):567-70.